|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's range||1.3400 - 1.7000|
|52-week range||1.3400 - 32.8700|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||12 Apr 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
SAN LEANDRO, Calif., March 30, 2022--Nanomix Corporation (OTCBB: NNMX, NNMXD), a leader in the development of mobile, affordable, point-of-care diagnostics, announces the appointment of Vidur Sahney as Chief Operating Officer. Mr. Sahney brings to Nanomix more than 20 years of experience in operations, quality, validation, manufacturing and research. In this newly created executive management position, Mr. Sahney will manage and be responsible for Nanomix operations including manufacturing, assa
EMERYVILLE, Calif., March 02, 2022--Nanomix Corporation (OTCBB: NNMX) ("Nanomix" or the "Company"), a leader in the development of mobile, affordable, point-of-care diagnostics, today announced it has completed the previously announced reverse stock split of its outstanding shares of common stock at a ratio of 1-for-173. The reverse stock split was announced on June 29, 2021 in conjunction with the reverse merger with Boston Therapeutics.
EMERYVILLE, Calif., December 08, 2021--Nanomix Corporation (OTC: NNMX) ("Nanomix" or the "Company"), a leader in the development of mobile, affordable, point-of-care diagnostics, today announced confirmation of registration from the Medicines & Healthcare products Regulatory Agency (MHRA) of the United Kingdom for the Nanomix eLab system and the S1 Panel Cartridge.